Literature DB >> 17588632

Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transduction.

Sachiko Hirosue1, Karin Senn, Nathalie Clément, Mathieu Nonnenmacher, Laure Gigout, R Michael Linden, Thomas Weber.   

Abstract

Over the past decade, adeno-associated (AAV) virus has emerged as an important vector for gene therapy. As a result, understanding its basic biology, including intracellular trafficking, has become increasingly important. Here, we describe the effect of inhibiting dynein function or altering the state of microtubule polymerization on rAAV2 transduction. Overexpression of dynamitin, resulting in a functional inhibition of the minus-end-directed microtubule motor protein dynein, did not inhibit transduction. Equally, treatment of cells with nocodazole, or concentrations of vinblastine that result in the disruption of microtubules, had no significant effect on transduction. In contrast, high concentrations of Taxol and vinblastine, resulting in microtubule stabilization and the formation of tubulin paracrystals respectively, reduced rAAV2 transduction in a vector-dose-dependent manner. These results demonstrate that AAV2 can infect HeLa cells independently of dynein function or an intact microtubule network.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17588632      PMCID: PMC2099573          DOI: 10.1016/j.virol.2007.05.009

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  50 in total

Review 1.  Cytoarchitecture and physical properties of cytoplasm: volume, viscosity, diffusion, intracellular surface area.

Authors:  K Luby-Phelps
Journal:  Int Rev Cytol       Date:  2000

2.  Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry.

Authors:  Aravind Asokan; Julie B Hamra; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Richard J Samulski
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Shiga toxin facilitates its retrograde transport by modifying microtubule dynamics.

Authors:  Heidi Hehnly; David Sheff; Mark Stamnes
Journal:  Mol Biol Cell       Date:  2006-08-02       Impact factor: 4.138

4.  Cytoplasmic trafficking of the canine parvovirus capsid and its role in infection and nuclear transport.

Authors:  M Vihinen-Ranta; W Yuan; C R Parrish
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors.

Authors:  J S Bartlett; R Wilcher; R J Samulski
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Dynamin is required for recombinant adeno-associated virus type 2 infection.

Authors:  D Duan; Q Li; A W Kao; Y Yue; J E Pessin; J F Engelhardt
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.

Authors:  C E Wobus; B Hügle-Dörr; A Girod; G Petersen; M Hallek; J A Kleinschmidt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Integrin alphaVbeta5 is not involved in adeno-associated virus type 2 (AAV2) infection.

Authors:  J Qiu; K E Brown
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

9.  Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation.

Authors:  S Sanlioglu; P K Benson; J Yang; E M Atkinson; T Reynolds; J F Engelhardt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

10.  The interaction of heparin sulfate and adeno-associated virus 2.

Authors:  J Qiu; A Handa; M Kirby; K E Brown
Journal:  Virology       Date:  2000-03-30       Impact factor: 3.616

View more
  16 in total

Review 1.  Recombinant adeno-associated virus transduction and integration.

Authors:  Brian R Schultz; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-05-20       Impact factor: 11.454

2.  Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network.

Authors:  Ping-Jie Xiao; R Jude Samulski
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

3.  Ciliary beating amplitude controlled by intracellular Cl- and a high rate of CO2 production in ciliated human nasal epithelial cells.

Authors:  Taka-Aki Inui; Kentaro Murakami; Makoto Yasuda; Shigeru Hirano; Yukiko Ikeuchi; Haruka Kogiso; Shigekuni Hosogi; Toshio Inui; Yoshinori Marunaka; Takashi Nakahari
Journal:  Pflugers Arch       Date:  2019-05-18       Impact factor: 3.657

Review 4.  Perspectives in Diagnosis and Treatment of Rabies Viral Encephalitis: Insights from Pathogenesis.

Authors:  Anita Mahadevan; M S Suja; Reeta S Mani; Susarala K Shankar
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

5.  Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates.

Authors:  Kye-Il Joo; Yun Fang; Yarong Liu; Liang Xiao; Zhen Gu; April Tai; Chi-Lin Lee; Yi Tang; Pin Wang
Journal:  ACS Nano       Date:  2011-04-13       Impact factor: 15.881

6.  Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway.

Authors:  Mathieu Nonnenmacher; Thomas Weber
Journal:  Cell Host Microbe       Date:  2011-12-15       Impact factor: 21.023

7.  Densovirus infectious pathway requires clathrin-mediated endocytosis followed by trafficking to the nucleus.

Authors:  Agnès Vendeville; Marc Ravallec; Françoise-Xavière Jousset; Micheline Devise; Doriane Mutuel; Miguel López-Ferber; Philippe Fournier; Thierry Dupressoir; Mylène Ogliastro
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

8.  Parvovirus particles and movement in the cellular cytoplasm and effects of the cytoskeleton.

Authors:  Sangbom Michael Lyi; Min Jie Alvin Tan; Colin R Parrish
Journal:  Virology       Date:  2014-04-25       Impact factor: 3.616

9.  Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays.

Authors:  Boris Gorovits; Michele Fiscella; Mike Havert; Eugen Koren; Brian Long; Mark Milton; Shobha Purushothama
Journal:  AAPS J       Date:  2020-01-06       Impact factor: 4.009

10.  Strategy to detect pre-existing immunity to AAV gene therapy.

Authors:  L Falese; K Sandza; B Yates; S Triffault; S Gangar; B Long; L Tsuruda; B Carter; C Vettermann; S J Zoog; S Fong
Journal:  Gene Ther       Date:  2017-11-06       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.